BIO-TECHNE CORP (TECH) Stock Price & Overview
NASDAQ:TECH • US09073M1045
The current stock price of TECH is 53.89 USD. Today TECH is down by -3.58%. In the past month the price decreased by -18.17%. In the past year, price decreased by -16.28%.
TECH Key Statistics
- Market Cap
- 8.431B
- P/E
- 27.36
- Fwd P/E
- 24.00
- EPS (TTM)
- 1.97
- Dividend Yield
- 0.55%
TECH Stock Performance
TECH Stock Chart
TECH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TECH. When comparing the yearly performance of all stocks, TECH is a bad performer in the overall market: 81.04% of all stocks are doing better.
TECH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TECH. TECH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
TECH Earnings
On February 4, 2026 TECH reported an EPS of 0.46 and a revenue of 295.88M. The company beat EPS expectations (3.95% surprise) and missed revenue expectations (-0.04% surprise).
TECH Forecast & Estimates
23 analysts have analysed TECH and the average price target is 76.73 USD. This implies a price increase of 42.37% is expected in the next year compared to the current price of 53.89.
For the next year, analysts expect an EPS growth of 4.66% and a revenue growth 0.73% for TECH
TECH Groups
Sector & Classification
TECH Financial Highlights
Over the last trailing twelve months TECH reported a non-GAAP Earnings per Share(EPS) of 1.97. The EPS increased by 8.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.58% | ||
| ROA | 3.17% | ||
| ROE | 3.98% | ||
| Debt/Equity | 0.13 |
TECH Ownership
TECH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20.22 | 194.933B | ||
| DHR | DANAHER CORP | 23.02 | 142.794B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 132.94 | 46.674B | ||
| A | AGILENT TECHNOLOGIES INC | 17.2 | 33.39B | ||
| IQV | IQVIA HOLDINGS INC | 13.34 | 30.274B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 26.17 | 25.64B | ||
| ILMN | ILLUMINA INC | 24.07 | 19.595B | ||
| WAT | WATERS CORP | 20.91 | 18.787B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.32 | 17.579B | ||
| MEDP | MEDPACE HOLDINGS INC | 27.99 | 13.222B | ||
| RVTY | REVVITY INC | 16.6 | 10.949B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 9.484B | ||
| CRL | CHARLES RIVER LABORATORIES | 15.88 | 8.925B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TECH
Company Profile
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Company Info
BIO-TECHNE CORP
614 Mckinley Pl N E, Suite 1500
Minneapolis MINNESOTA 55413 US
CEO: Charles Kummeth
Employees: 3100
Phone: 16123798854
BIO-TECHNE CORP / TECH FAQ
Can you describe the business of BIO-TECHNE CORP?
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
What is the stock price of BIO-TECHNE CORP today?
The current stock price of TECH is 53.89 USD. The price decreased by -3.58% in the last trading session.
Does BIO-TECHNE CORP pay dividends?
BIO-TECHNE CORP (TECH) has a dividend yield of 0.55%. The yearly dividend amount is currently 0.32.
How is the ChartMill rating for BIO-TECHNE CORP?
TECH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of BIO-TECHNE CORP (TECH) based on its PE ratio?
The PE ratio for BIO-TECHNE CORP (TECH) is 27.36. This is based on the reported non-GAAP earnings per share of 1.97 and the current share price of 53.89 USD.
Can you provide the growth outlook for BIO-TECHNE CORP?
The Revenue of BIO-TECHNE CORP (TECH) is expected to grow by 0.73% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for BIO-TECHNE CORP?
BIO-TECHNE CORP (TECH) has a market capitalization of 8.43B USD. This makes TECH a Mid Cap stock.